Fate Therapeutics (FATE) Competitors $1.11 -0.02 (-1.77%) Closing price 08/21/2025 04:00 PM EasternExtended Trading$1.11 0.00 (-0.36%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. MBX, ATYR, SLDB, AUTL, PRME, ERAS, ETON, CGEM, TNXP, and ITOSShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include MBX Biosciences (MBX), aTyr Pharma (ATYR), Solid Biosciences (SLDB), Autolus Therapeutics (AUTL), Prime Medicine (PRME), Erasca (ERAS), Eton Pharmaceuticals (ETON), Cullinan Therapeutics (CGEM), Tonix Pharmaceuticals (TNXP), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors MBX Biosciences aTyr Pharma Solid Biosciences Autolus Therapeutics Prime Medicine Erasca Eton Pharmaceuticals Cullinan Therapeutics Tonix Pharmaceuticals iTeos Therapeutics MBX Biosciences (NYSE:MBX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Is MBX or FATE more profitable? MBX Biosciences has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,025.05%. MBX Biosciences' return on equity of 0.00% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Fate Therapeutics -2,025.05%-50.95%-36.76% Do institutionals and insiders believe in MBX or FATE? 97.5% of Fate Therapeutics shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by insiders. Comparatively, 5.5% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate MBX or FATE? MBX Biosciences currently has a consensus target price of $37.63, indicating a potential upside of 165.90%. Fate Therapeutics has a consensus target price of $3.30, indicating a potential upside of 197.30%. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Fate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 Which has higher valuation and earnings, MBX or FATE? MBX Biosciences has higher earnings, but lower revenue than Fate Therapeutics. MBX Biosciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/A-$4.54-3.12Fate Therapeutics$8.47M15.11-$186.26M-$1.45-0.77 Does the media prefer MBX or FATE? In the previous week, Fate Therapeutics had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 7 mentions for Fate Therapeutics and 5 mentions for MBX Biosciences. Fate Therapeutics' average media sentiment score of 0.59 beat MBX Biosciences' score of 0.15 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryFate Therapeutics beats MBX Biosciences on 7 of the 13 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.32M$3.09B$5.79B$9.58BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-0.7720.4330.4725.19Price / Sales15.11377.07454.63115.75Price / CashN/A43.0937.1558.42Price / Book0.497.919.036.24Net Income-$186.26M-$54.72M$3.26B$265.30M7 Day Performance1.83%-0.09%0.40%-0.84%1 Month Performance-10.48%4.49%3.23%-1.53%1 Year Performance-70.56%10.15%29.53%17.73% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics4.0011 of 5 stars$1.11-1.8%$3.30+197.3%-71.6%$130.32M$8.47M-0.77550Analyst RevisionGap UpMBXMBX Biosciences2.588 of 5 stars$14.57-1.0%$37.63+158.2%N/A$489.47MN/A-3.2136ATYRaTyr Pharma2.1029 of 5 stars$4.91+0.2%$21.25+332.8%+163.3%$480.14M$230K0.0053News CoverageShort Interest ↑SLDBSolid Biosciences3.4981 of 5 stars$6.03-1.3%$15.00+148.8%-43.1%$475.78M$8.09M0.00100AUTLAutolus Therapeutics3.0645 of 5 stars$1.88+5.6%$9.12+385.1%-57.1%$473.73M$10.12M-2.24330Gap UpPRMEPrime Medicine2.8558 of 5 stars$3.50-2.0%$8.92+154.8%-26.8%$471.01M$4.96M-1.71234Gap DownERASErasca1.9941 of 5 stars$1.53-6.7%$4.29+180.1%-47.2%$465.22MN/A0.00120ETONEton Pharmaceuticals2.4084 of 5 stars$16.37-3.9%$29.67+81.2%+312.8%$456.97M$39.01M0.0020Positive NewsInsider TradeCGEMCullinan Therapeutics1.7506 of 5 stars$7.95+3.8%$28.60+259.7%-57.4%$452.51MN/A0.0030News CoverageAnalyst ForecastAnalyst RevisionTNXPTonix Pharmaceuticals3.0992 of 5 stars$40.07-22.0%$70.00+74.7%-0.4%$450.13M$10.09M-1.0250High Trading VolumeITOSiTeos Therapeutics2.3616 of 5 stars$10.11flat$15.50+53.3%-41.7%$446.92M$35M0.0090Positive News Related Companies and Tools Related Companies MBX Biosciences Alternatives aTyr Pharma Alternatives Solid Biosciences Alternatives Autolus Therapeutics Alternatives Prime Medicine Alternatives Erasca Alternatives Eton Pharmaceuticals Alternatives Cullinan Therapeutics Alternatives Tonix Pharmaceuticals Alternatives iTeos Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access